Method for Treating Retinal Conditions Using an Intraocular Tamponade
Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition.
1 .- 9 . (canceled)
10 . A composition comprising at least one fatty acid glycerol ester, wherein the composition is further defined as:
having a surface tension of less than 50 dynes/cm;
being bioresorbable; and
injectable in a vitreous cavity during or after a vitrectomy procedure.
11 . The composition of claim 10 , further defined as having a surface tension ranging from 20 to 30 dynes/cm.
12 . The composition of claim 10 , further defined as having a density below 1.0.
13 . The composition of claim 12 , further defined as having a density between 0.90 and 1.
14 . The composition of claim 10 , further defined as having a density adapted for treating a detachment of a lower portion of a retina that is above 1.
15 . The composition of claim 14 , further defined as having a density between 1 and 1.5.
16 . The composition of claim 10 , further defined as having a dynamic viscosity ranging from 20 to 60 mPa·s at a temperature of 20° C.
17 . The composition of claim 16 , further defined as having a dynamic viscosity ranging from 25 to 55 mPa·s at a temperature of 20° C.
18 . The composition of claim 17 , further defined as having a dynamic viscosity ranging from 27 to 33 mPa·s at a temperature of 20° C.
19 . The composition of claim 10 , further defined as having a refractive index ranging from 1.40 to 1.50.
20 . The composition of claim 19 , further defined as having a refractive index ranging from 1.44 to 1.46.
21 . The composition of claim 20 , further defined as having a refractive index ranging from 1.449 to 1.451.
22 . The composition of claim 10 , further comprising at least one lipophilic therapeutic agent.
23 . The composition of claim 10 , further comprising at least one lipophilic therapeutic agent and at least one bioresorbable fatty acid glycerol ester, wherein the composition is a solution comprising at least 90% w/w of C6-C20 glycerol ester, in weight to weight of total composition, a therapeutic agent in an amount of more than 0 to 5.9% w/w, in weight to weight of total composition, with the therapeutic agent being dissolved in the fatty acid glycerol ester.
24 . The composition of claim 23 , wherein the bioresorbable fatty acid glycerol ester is further defined as a non-water miscible C6-C20 glycerol ester.
25 . The composition of claim 10 , wherein the fatty acid glycerol ester is a medium-chain triglyceride.
26 . A method of treating a retinal disorder comprising:
obtaining a composition of claim 10 ; and
administering it to a patient.